ASX:IDXHealthcare
Integral Diagnostics H1 2026 Thin 1.8% Net Margin Tests Bullish Growth Narratives
Integral Diagnostics (ASX:IDX) has taken a step forward in H1 2026, with trailing twelve month revenue of A$767.9 million and basic EPS of A$0.038. H2 2025 on its own delivered revenue of A$374.3 million and basic EPS of A$0.0139. The company has seen revenue move from A$238.4 million in H2 2024 to A$252.9 million in H1 2025 and then to A$374.3 million in H2 2025. Net income shifted from A$6.1 million to a A$0.4 million loss and then to A$5.1 million over those same periods, setting up a...